**Article**

**Integrated DNA Copy Number and Expression Profiling Identifies IGF1R as a Prognostic Biomarker in Pediatric Osteosarcoma**

Aaron M. Taylor 1,2,3, Jiayi M. Sun 2,3, Alexander Yu 2, Horatiu Voicu 4, Jianhe Shen 2, Donald A. Barkauskas 5, Timothy J. Triche 6, Julie M. Gastier-Foster 7, Tsz-Kwong Man 2,4 and Ching C. Lau 1,2,3,4,7,*

1. Introduction

Pediatric primary bone cancer is a rare malignancy that accounts for 6% of all cancers from birth to the age of 20 [1]. Osteosarcoma, a mesenchymal malignant tumor with an incidence rate of approximately 400 cases a year in the United States [1], is the most common bone cancer in this group. Most osteosarcoma cases are sporadic, with mutations in TP53 and RB1 common to 40% or more of these tumors [2]. Chromosomal defects due to chromosomal instability are very common in osteosarcoma, but no translocations are particularly disease-defining [3].
There has been significant previous research into the molecular characteristics of osteosarcoma, which has focused most heavily on the Notch and Wnt pathways. It has been shown that inhibiting Wnt signaling is effective at limiting both tumorigenesis and the metastatic potential of osteosarcoma in a murine model [4,5], and that the inhibition of Notch signaling decreases cell proliferation and tumor size in cells and mice, respectively [6]. A recent study which integrated copy number, methylation, and gene expression profiling on 10 primary tumor samples identified RUNX2, DOCK5, TNFSRF10A/D, and several Histone cluster 2 genes with possible roles in osteosarcoma tumorigenesis [7]. The overexpression of ezrin, a cytoskeletal linker protein, has a vital role in the metastatic potential of osteosarcoma and was associated with poor prognosis in pediatric patients [8]. Integrated analyses of gene expression, copy number, and methylation profiles in osteosarcoma cell lines has revealed a potential role for gene silencing and chromosomal aberrations in osteosarcoma tumorigenesis, particularly in the known oncprotein c-Myc [7,9].

Micro-RNAs (miRNAs) are emerging as a critical factor in the formation and proliferation of osteosarcoma, with members of the miRNA-29 family such as miR-29a, miR-29b, and miR-29c playing an essential role [10]. miR-210 has also been found to be upregulated in pediatric osteosarcoma with prognostic implications [11]. Further work has shown that micro-RNA (miRNA) expression levels can be used to predict response to therapy [12,13], particularly the maternally expressed miRNA in the 14q region [14]. miRNAs involved in the Notch and Wnt pathways are also frequently aberrantly expressed, with Notch regulator miR-199b-5p playing a direct role in osteosarcoma pathogenesis [15,16]. Several other miRNAs are being explored due to their known dysregulation in osteosarcoma for potential therapeutic and diagnostic applications [17].

Despite the above advances in the molecular mechanisms involved in pediatric osteosarcoma, an overall survival (OS) rate of 68% has remained relatively unchanged over the past several decades [18]. Current treatment for pediatric osteosarcoma consists mainly of surgical tumor removal and chemotherapy. This treatment has been optimized in recent years to include a common regimen of neoadjuvant chemotherapy, surgery, radiation, and post-operative chemotherapy [2]. Neoadjuvant chemotherapy consists of a non-specific three-drug regime of high-dose methotrexate, doxorubicin, and cisplatin [2]. Despite the common application of neoadjuvant chemotherapy in treatment centers in the USA and abroad, it has not been shown to have any significant effect on event-free survival (EFS) [19], although tumor necrosis following therapy correlates with EFS [20]. The presence of metastases at diagnosis, particularly common in the lung, remains the most effective prognostic indicator for patient survival [21]. Clinical trials to determine the effectiveness of potential targeted chemotherapeutic agents based on results from previous studies have so far been unsuccessful [22,23], and have failed to discover a more effective treatment regimen for high-risk patients.

In order to discover prognostic biomarkers with potential therapeutic applications, we collected samples from 226 unique patients and performed array-based copy number and gene expression profiling. While previous studies suffered from a limited sample size, a lack of clinical information, or a reliance on cell lines, this study uniquely utilizes a large cohort of primary tumor samples with paired patient survival data. We identified biomarkers in both copy number and expression platforms associated with survival, and integrated these data types in order to determine how expression is altered by copy number changes. Using these methods, we determined that IGFR1 is frequently overexpressed due to large increases in copy number changes, and that both copy number and expression can be used as prognostic biomarkers and potential therapeutic targets.

2. Results

2.1. NMF Clustering of Gene Expression Data Identifies Two Distinct Clusters

Non-Negative Matrix Factorization (NMF) analysis was performed on the 103 samples profiled using the Human Exon 1.0 ST (HuEx) array and we identified two distinct clusters (Supplementary Figures S1 and S2). To understand the biology underlying the clusters, dif-
ferentially expressed genes which contributed to the NMF features were extracted (Figure 1, Supplementary Table S1). The top 10 processes overrepresented in the differentially expressed gene list were derived using MetaCore Pathway Analysis (Table 1). All features present on the Affymetrix Human Exon 1.0 ST array were used as the background. Differentially expressed genes involved in cell adhesion (including integrin priming, leucocyte chemotaxis, and cadherins) and development (regulation of angiogenesis, blood vessel morphogenesis, ossification and bone remodeling, regulation of epithelial-to-mesenchymal transition, and skeletal muscle development) pathways were overexpressed. Although the NMF clusters were significantly associated with both event-free (Wald test $p = 0.0085$) and overall (Wald test $p = 0.0438$) survival, adding initial metastatic status to the model abrogated their prognostic ability (Supplementary Figure S3), suggesting that the NMF clusters may be a surrogate for initial metastatic status (Figure 1).

Table 1. Process networks enriched for differential expression from Metacore.

| # Process Networks | Data Total | $p$-Value | FDR | Network Objects from Active Data |
|--------------------|------------|-----------|-----|---------------------------------|
| 1 Cell adhesion_Integrin priming | 9 | $1.05 \times 10^{-5}$ | $6.71 \times 10^{-4}$ | ACTA2, G-protein alpha-i family, PIB4, SDF-1, SOS, |
| 2 Leucocyte chemotaxis_Cadherins | 7 | $1.42 \times 10^{-4}$ | $1.52 \times 10^{-3}$ | ICAM-1, VLA-4, BCL2A1, ITGB2, |
| 3 Regulation of angiogenesis | 8 | $2.28 \times 10^{-4}$ | $3.38 \times 10^{-4}$ | TIE2, Ang-1, |
| 4 Blood vessel morphogenesis_Ossification and bone remodeling | 5 | $1.23 \times 10^{-3}$ | $4.72 \times 10^{-4}$ | COL1A2, COL3A1, |
| 5 Regulation of epithelial-to-mesenchymal transition | 4 | $3.45 \times 10^{-3}$ | $8.82 \times 10^{-4}$ | SNAIL1, ZEB1, |
| 6 Skeletal muscle development | 6 | $1.65 \times 10^{-3}$ | $8.82 \times 10^{-4}$ | MYH7, MYH9, |

**Figure 1.** Differentially expressed genes. Samples with HuEx data ($n = 103$) are listed along the x-axis and expression probesets are hierarchically clustered (complete linkage, average distance) on the y-axis. mRNA expression clusters 1 (blue) and 2 (red) are annotated.
### Table 1. Process networks enriched for differential expression from Metacore.

| # | Process Networks                                             | In Data | Total | p-Value     | FDR          | Network Objects from Active Data                                                                                                                                 |
|---|-------------------------------------------------------------|---------|-------|-------------|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | Cell adhesion_Integrin priming                             | 9       | 110   | $1.05 \times 10^{-5}$ | $6.71 \times 10^{-4}$ | ACTA2, G-protein alpha-i family, PIB4, SDF-1, SOS, Actin, Collagen III, PLC-beta, SOS1                                                                                     |
| 2 | Cell adhesion_Leucocyte chemotaxis                          | 12      | 205   | $1.09 \times 10^{-5}$ | $6.71 \times 10^{-4}$ | G-protein alpha-i family, VCAM1, PIB4, Galpha(i)-specific EDG GPCRs, CCL2, CCL13, SDF-1, CXCL13, Actin, LPA3 receptor, PLC-beta, Galpha(q)-specific EDG GPCRs |
| 3 | Development_Regulation of angiogenesis                       | 11      | 223   | $1.25 \times 10^{-4}$ | $4.66 \times 10^{-3}$ | FAP48, G-protein alpha-i1, Angiopoietin 1, Epherin-A receptors, G-protein alpha-i family, IL-6, CCL2, PGAR, N-cadherin, SOS, PLC-beta                                       |
| 4 | Development_Blood vessel morphogenesis                      | 11      | 228   | $1.52 \times 10^{-4}$ | $4.66 \times 10^{-3}$ | G-protein alpha-i1, Angiopoietin 1, G-protein alpha-i family, VCAM1, ErbB4, Galpha(i)-specific EDG GPCRs, PGAR, SDF-1, PLGF, SOS, HGF receptor (Met)                 |
| 5 | Development_Ossification and bone remodeling                | 8       | 157   | $8.88 \times 10^{-4}$ | $2.18 \times 10^{-2}$ | AEBP1, Frizzled, SFRP4, OSF-2, DMP1, MEPE, Osteomodulin, Bone sialoprotein                                                                                          |
| 6 | Cell adhesion_Cadherins                                     | 8       | 180   | $2.13 \times 10^{-3}$ | $3.53 \times 10^{-2}$ | Frizzled, SFRP4, DKK1, N-cadherin, PTPR-zeta, WIFI, Actin, HGF receptor (Met)                                                                                     |
| 7 | Development_EMT_Regulation of epithelial-to-mesenchymal transition | 9      | 225   | $2.33 \times 10^{-3}$ | $3.53 \times 10^{-2}$ | HGF, ACTA2, Frizzled, G-protein alpha-i family, N-cadherin, SOS, Actin, HGF receptor (Met), Collagen III                                                          |
| 8 | Development_Skeletal muscle development                     | 7       | 144   | $2.46 \times 10^{-3}$ | $3.53 \times 10^{-2}$ | ACTA2, ER81, Actin muscle, ITGA11, ACTG2, Actin, HGF receptor (Met)                                                                                           |
| 9 | Inflammation_Protein C signaling                            | 6       | 108   | $2.59 \times 10^{-3}$ | $3.53 \times 10^{-2}$ | G-protein alpha-i family, PIB4, Galpha(i)-specific EDG GPCRs, IL-6, Actin, PLC-beta                                                                                     |
| 10| Inflammation_Histamine signaling                            | 8       | 213   | $5.95 \times 10^{-3}$ | $6.28 \times 10^{-2}$ | Kappa chain (lg light chain), G-protein alpha-i family, VCAM1, PIB4, IL-6, CCL2, Actin, PLC-beta                                                                       |

### 2.2. mRNA Expression Predicts Clinical Outcomes

In order to determine which genes were associated with clinical outcomes that are independent of initial metastasis, which is an existing prognostic factor at diagnosis, the sample set profiled on the Human Exon 1.0 ST array was utilized as a discovery cohort (103 samples), and a separate cohort profiled using the U133 Plus 2.0 array was used for validation (64 samples). The top 2.5% (437) most variable features (Supplementary Figure S4) were utilized for survival analysis. For each feature, multivariate Cox proportional hazards models for both event-free survival (EFS) and overall survival (OS) time were created. A total of seven features were significantly associated after false discovery correction with overall survival (Benjamini–Hochberg-corrected Wald test, $p < 0.05$). Using only these features for the analysis, they were also significantly associated with event-free survival before false discovery correction across all genes. High expression of these features was associated with better prognosis (Supplementary Table S2).
To validate our results, probesets from the U133 array mapping to the same genes as the prognostically significant HuEx features were selected for survival analysis. A total of four U133 features, mapping to the same genes as three HuEx features, showed prognostic significance for both overall and event-free survival (Table 2). These features mapped to fibroblast growth factor receptor 2 (FGFR2), fin bud initiation factor homolog (FIBIN), pleiotrophin (PTN), and diacylglycerol kinase iota (DGKI). Higher FGFR2 and FIBIN expression is associated with better survival outcomes in both the discovery and validation set. The HuEx feature that matched to both PTN and DGKI correlated with better prognosis in the discovery set, as was the DGKI feature in the validation set. However, PTN expression in the validation set was deleterious. Samples with high expression of FGFR2 showed significantly better prognosis (Figure 2).

![Kaplan–Meier curves showing survival rate difference between patients with high and low expression of FGFR2.](image)

Figure 2. Kaplan–Meier curves showing survival rate difference between patients with high and low expression of FGFR2. (a) Event-free survival and (b) overall survival in the HuEx discovery cohort (n = 88). (c) Event-free survival and (d) overall survival in the U133 validation cohort (n = 60). FGFR2 expression stratified into high (red) and low (blue) expression groups at the 50th percentile.
2.3. Characterization of Osteosarcoma Copy Number Aberrations

To identify DNA copy number aberrations associated with osteosarcoma, segmentation data from 147 osteosarcoma DNA samples were analyzed using GISTIC (Supplementary Figure S5, Supplementary Table S3). In summary, we observed 77 significantly altered copy number regions composed of 25 amplifications and 52 deletions (residual q-value < 0.05). As a comparison, we contrasted our results with several osteosarcoma array CGH and probe-based studies [24–27]. Of the top 10 recurrent amplifications or deletions, 7 and 2, respectively, were also reported in previous studies (Table 3). Among these regions, the minimum proportion of samples with at least a moderate level of amplification or deletion of that copy number aberration was 33.3%, an indication of a highly rearranged genome that is characteristic of pediatric osteosarcoma patients. Recurrent copy number changes were identified in regions containing canonical osteosarcoma-associated genes, such as MYC and RB1, as well as in more novel regions such as 13q34.

A majority of the top 10 most frequently highly amplified regions have been reported, in previous studies including 17p11.2 (TOP3A, FLI1), 8q24.21 (MYC), 1q21.3 (MCL1, BNIPL), 19p13.2 (JUNB, NFIX), 6p21.1 (CDC5L), 19q12 (CCNE1) and 15q26.3 (IGF1R). High-frequency amplification of 17p11.2 was observed in 30.6% (45/147) of cases. This region encompasses topoisomerase III alpha (TOP3A), a key gene involved in many DNA structural maintenance processes and the transcription factor friend leukemia virus integration 1 (FLI1). Using segmentation summarized copy number values, we found that TOP3A and FLI1 are very positively correlated (rho > 0.5 for comparisons in both genes) with gene expression in both HuEx and U133 platforms. Recurrent copy number gain of 8q24.21 involving the transcription factor coding gene MYC is associated with higher expression in both datasets. Out of all the cases, 17% (25/147) exhibited high-frequency amplification of 19q12, which overlaps with cyclin E1 (CCNE1). We identified that CCNE1 copy number is also highly correlated with gene expression in HuEx (rho = 0.53, 3828112) and U133 (rho = 0.548, 213523_at) datasets. Other regions of amplification also detected in previous studies include 1p31.1 (NEGR1), 8q24.23 and 12q14.1 (CDK4).

We also detected amplification in less commonly reported or novel regions such as 20p13 and 13q34. Amplification of 20p13 has been reported sporadically in previous osteosarcoma array CGH studies, but is not normally recognized as a commonly amplified region in osteosarcoma [28,29]. In our dataset, we identified roughly 20.4% (30/147) of samples with an amplification of 20p13. GISTICs reported region limits in 20p13 overlap with signal-regulatory protein delta (SIRPD) and beta 1 (SIRPB1), two members of the SIRP family of genes. While not much is known about SIRPD, the amplification of SIRPB1 has
been associated with primary myelofibrosis, a disease of the bone marrow [30]. Recurrent amplification of 13q34 is a common feature in many types of cancers, but it has not yet been widely explored in osteosarcoma [31]. Several genes located in 13q34 have been associated with a worse prognosis in other cancers, including CUL4A and TFDP1, IRS2 and CDC16 [32,33]. Using gene-level copy number, we identified that CUL4A and TFDP1 copy numbers strongly correlate with expression, indicating a potential mechanism for the change in expression. We did not, however, identify an association with poor outcome, as seen in previous reports.

Table 3. Top 10 frequently amplified (red) and deleted (blue) regions from GISTIC (n = 147).

| Cytoband | Location(Mbs) | Width(Mbs) | Residual q Value | Frequency | High Frequency | Key Genes |
|----------|---------------|------------|-----------------|-----------|----------------|-----------|
| 17p11.2  | chr17:18.123–18.237 | 0.114 | 0 | 44.9 | 30.6 | TOP3A, FLI1 * |
| 8q24.21 | chr8:128.357–128.772 | 0.415 | 0 | 46.9 | 27.2 | MYC * |
| 20p13   | chr20:1.52–1.529 | 0.009 | 0 | 49 | 20.4 | |
| 15q26.3 | chr15:99.366–99.408 | 0.043 | 0 | 42.2 | 20.4 | IGF1R * |
| 1q21.3  | chr1:149.996–151.21 | 1.214 | 0.001 | 48.3 | 19 | |
| 13q34   | chr13:105.817–114.882 | 9.065 | 0.116 | 44.2 | 19 | |
| 19p13.2 | chr19:12.686–13.498 | 0.812 | 0 | 43.5 | 18.4 | |
| 6p21.1  | chr6:43.323–44.511 | 1.187 | 0 | 40.1 | 17 | |
| 19q12   | chr19:30.082–30.306 | 0.224 | 0 | 40.1 | 17 | |
| 8p11.1  | chr8:41.441–50.441 | 9 | 0.033 | 50.3 | 16.3 | |

* There were no high-frequency homozygous deletions deleted with significance. * Regions seen in previous studies. High amplification/deletion frequency is determined algorithmically by GISTIC.

In addition to the most frequently amplified regions, we also detected 5p15.33 amplification in 40.1% (58/147) and high amplification in 15% (22/147) of cases. This region overlaps with telomerase transcriptase (TERT), an enzyme involved in chromosome end maintenance through the addition of TTAGGG sequences to the 3’ end of telomeres. Chromosome end maintenance, through either telomerase or alternative lengthening of telomeres (ALT), is a pathway through which cancer cells can overcome cell senescence. Unlike other cancers, osteosarcoma has a higher prevalence of ALT in relation to TERT [34]. However, we did not identify a significant correlation between TERT copy number and expression, indicating that TERT expression may be regulated by more complicated mechanisms.

Among the top 10 most recurrent regions with copy number loss, 13q14.2 (RB1) and 3q13.31 (LSAMP/LSAMP-AS3) have also been seen in previous studies. The association between mutations in the Retinoblastoma 1 (RB1) gene and predisposition to osteosarcoma are well known [35,36]. We identified that focal copy number loss of RB1 was also associated with lower expression in both HuEx (rho = 0.52, 3489020) and U133 (rho = 0.53, 203132_at). While we did not identify a correlation between LSAMP/LSAMP-AS3 copy number and expression, deletion of 3p13.31 has been associated with prognosis in multiple osteosarcoma studies and is significantly associated with event-free survival independently (p-value = 0.026) in our data [37–39]. Three recurrently deleted regions from GISTIC were mapped to 17p13.1, one of which has a wide-peak region 20 Kb away from the beginning.
of TP53. GISTICs’ wide peak regions encompass a stringent narrow region and the whole region of deletion extends far past its boundaries. To evaluate TP53 deletion on a gene level, we looked at the gene-centric data from GISTIC and found that it was deleted 55.8% of the time (82/147 cases). While TP53 copy number was not directly correlated with gene expression in our data, the mechanism for loss of TP53 function may be achieved through other mechanisms such as mutations or structural abnormalities. Other regions with deletion corresponding with previous studies include 6p27, 6p12, 10q26.3 and 10p15.3. The novel regions of deletion that we detected include 4q35.2 (DUX4), 16q24.3 (PRDM7, GAS8) and 20q13.33 (MYT1). DUX4 is part of the double homeobox gene family and the deletion identified in our data overlaps with other members of that family. A recent study of small cell osteosarcoma identified 10/36 with a gene fusion involving DUX4 and CIC [40]. Myelin transcription factor 1 (MYT1) is not reportedly involved in normal cell cycle regulation; however, cells with depleted MYT1 have increased CDK1 activity, leading to faster recovery of cell cycle checkpoints due to DNA damage [41]. Therefore, MYT1 depletion in osteosarcoma may contribute to the increased cell proliferation in the presence of chromosomal aberrations.

2.4. IGF1R Amplification Is Associated with Higher Expression and Worse Prognosis

To evaluate the clinical significance of these copy number changes, we calculated weighted copy number estimates of GISTICs significantly amplified and deleted regions from segmentation data and evaluated their association with survival (Table 4). Weighted copy number estimates were calculated by overlapping copy number segments with GISTIC regions and weighting the copy number of each segment based on its overlap with the GISTIC region. After Benjamini–Hochberg multiple testing correction, the amplification of both chromosome 8q24.21 (MYC) and 15q26.3 (IGF1R) was associated with poor overall and event-free survival. Initial metastasis is a known prognostic marker for prognosis in many cancers, including osteosarcoma. Accounting for this factor in the survival model rendered 8q24.21 as no longer significant, likely due to MYC’s well-known role in cell growth and association with metastasis. The amplification of 15q26.3, which contains the insulin-like growth factor 1 receptor (IGF1R), is still significant in the presence of initial metastasis for both overall and event-free survival. IGF1R gene copy number was calculated using segmentation data and copy number as a continuous variable is significantly associated with both event-free survival ($p$-value = $4.78 \times 10^{-5}$) and overall survival ($p$-value = 0.0015) with consideration of initial metastasis.

Table 4. Survival Analysis of Significantly Amplified and Deleted Regions ($n$ = 126).

| Cytoband | Change | Genes                  | Full Model Including Initial Metastasis |
|---------|--------|------------------------|----------------------------------------|
|         |        |                        | OS $\quad$ p-Value $\quad$ EFS $\quad$ OS $\quad$ p-Value $\quad$ EFS |
| 15q26.3 | Amp    | IGFR1                  | 1.110 $\quad$ 9.00 $\times 10^{-3}$ $\quad$ 1.108 $\quad$ 3.40 $\times 10^{-2}$ $\quad$ 1.116 $\quad$ 1.30 $\times 10^{-2}$ $\quad$ 1.093 $\quad$ 2.25 $\times 10^{-1}$ |
| 8q24.21 | Amp    | MYC, POU5F1B, LOC727677 | 1.170 $\quad$ 1.10 $\times 10^{-2}$ $\quad$ 1.211 $\quad$ 4.00 $\times 10^{-3}$ |

OS—Overall Survival, EFS—Event-free Survival, HR—Hazard Ratio

To evaluate the biological effect of IGF1R amplification, we integrated copy number and gene expression data using samples with HuEx array data. We found a strong correlation between copy number and gene expression of IGF1R (Figure 3a). Noting the potential bias of samples with extremely high copy number amplification, we also observed good correlation just within the more numerous moderately amplified samples (CN < 10) (Figure 3b). Given the good association between these two platforms, we further evaluated the clinical significance of IGF1R expression. To achieve this, the probe mapping to IGF1R in the HuEx data was utilized to stratify the samples into high- and low-expression groups, based on a 75th percentile cutoff as a representation of amplified cases. The high expression group showed significantly (Wald test $p < 0.001$) poorer event-free and overall survival, even after accounting for initial metastasis in the model (Figure 3c,d). High IGF1R
probe (243358_at) expression in the U133 array cohort modeled as a continuous variable significantly predicted poorer event-free survival (Wald test \( p = 0.016 \)) and overall survival (Wald \( p = 0.027 \)), but the 75th percentile cutoff did not show significance.

To evaluate the biological effect of IGF1R amplification, we integrated copy number and gene expression data using samples with HuEx array data. We found a strong correlation between copy number and gene expression of IGF1R (Figure 3a). Noting the potential bias of samples with extremely high copy number amplification, we also observed good correlation just within the more numerous moderately amplified samples (CN < 10) (Figure 3b). Given the good association between these two platforms, we further evaluated the clinical significance of IGF1R expression. To achieve this, the probe mapping to IGF1R in the HuEx data was utilized to stratify the samples into high- and low-expression groups, based on a 75th percentile cutoff as a representation of amplified cases. The high expression group showed significantly (Wald test \( p < 0.001 \)) poorer event-free and overall survival, even after accounting for initial metastasis in the model (Figure 3c,d).

Figure 3. IGF1R copy number and expression correlation and survival analysis. (a) IGF1R expression and copy number correlation by spearman correlation using all samples (\( n = 93 \)) and (b) after removing high copy number outliers. (c) Event-free and (d) overall Kaplan–Meier survival curves showing survival rate difference between patients with high and low mRNA expression of IGF1R controlling for metastasis at diagnosis (\( n = 88 \)). Event-free survival models time to first relapse or death. Overall survival models time till death. IGF1R expression stratified into high (red) and low (blue) expression groups at the 75th percentile. Patient’s metastatic status at diagnosis is indicated in solid (non-metastatic) and dotted (metastatic) lines. Wald test \( p \)-value calculated using the stratified groups in a Cox proportional hazards model including metastasis at diagnosis as a covariate.

3. Discussion

Large-scale genomic characterization studies have improved the overall understanding of many cancers as evidenced by The Cancer Genome Atlas and the International Cancer Genome Consortium projects. While many genomics studies of osteosarcoma have been carried out previously, this study includes the largest number of pediatric osteosar-
coma cases to date. As such, the results from this study have benefited from the larger degree of statistical power which accompanies that. We have been able to identify chromosomal aberrations such as amplification of 20p13 and perturbation of 4q35.2, which have been identified sparsely in much smaller osteosarcoma sample sets previously with more significance. In addition, the matched copy number and expression data have allowed us to identify potential mechanisms behind gene expression changes, providing the opportunity for further therapeutic applications.

Copy number aberrations are characteristic of osteosarcoma and many known affected regions were validated in our study, reaffirming the complexity that defines the osteosarcoma genome. We confirmed the association seen in previous studies between copy number and expression in genes such as TOP3A, FLI1, CCNE1, MYC, IGF1R and RB1. While our results demonstrate that most of these recurrent copy number gains/losses show no significant association with survival, we did identify that the amplification of regions in 8q24.21, which overlaps with MYC, and 15q26.3, which overlaps with IGF1R, is associated with gene expression and patient survival. MYC is a well-known transcription factor with roles in cell proliferation, apoptosis and differentiation. MYC amplification and overexpression have been mechanistically linked in many cancers and have been associated with poor prognosis or increased cell proliferation in osteosarcoma cell lines and human tumors [42–46]. We observed that after the inclusion of initial metastasis in the survival model, MYC amplification is no longer prognostically significant. Given the integral role of MYC in cancer metastasis in osteosarcoma, this result is expected.

Our results show that both IGF1R copy number and expression can be used to predict both metastases and survival rates, independent of initial metastatic status. This is consistent with previous reports that implicate increased activity of IGF1R signaling in high-grade osteosarcoma, and that treatment with IGF1R inhibitors can successfully reduce proliferation of osteosarcoma cell lines [47]. IGF1R is a tyrosine kinase membrane receptor that binds both insulin and IGF-2, resulting in insulin receptor substrate protein phosphorylation [48]. The insulin-like growth factor signaling family includes ligands IGF1/IGF2 and receptors IGF1R/IGF2R and activates downstream PI3-kinase and Ras/Raf/ERK signaling pathways [49–51]. Osteosarcoma early peak incidence occurs around early adolescence, which coincides with peak expression of circulating IGF1/IGF2 [52]. IGF signaling has been implicated in tumorigenesis and progression of multiple sarcomas including osteosarcoma [53,54]. Interestingly, a previous study tested the ability of IGF1R copy number and expression levels to predict the response to targeted IGF1R antibody therapy in murine xenografts, which found no clear predictive power for either [55]. However, that study lacked the associated clinical outcome data needed to determine whether IGF1R expression or copy number could predict patient survival. IGF1R copy number was also previously shown to be elevated in a small study of 10 primary samples, and this copy number change was correlated with higher IGF1R mRNA expression [7]. Treatment with an anti-IGF1R antibody in mouse xenografts of osteosarcoma showed promising results [55], and this preclinical evaluation provided motivation for a phase II clinical trial testing an anti-IGF1R antibody in combination with mTOR inhibitor in several sarcomas [56]. This trial showed disappointing results. However, upon examination, the trial included only 11 osteosarcoma cases, of which only two cases showed strong immunohistochemistry expression of IGF1R, and no evaluation of IGF1R copy number was used to guide treatment. In combination with these previous findings, our results suggest that IGF1R expression is amplified in a subset of osteosarcoma due to increased IGF1R copy number, and that both can successfully stratify patients into high- and low-risk groups independent of initial metastatic status. Additionally, a Phase 1/2 clinical trial (NCT03746431) targeting IGF1R-overexpressing solid tumors with a radioimmunotherapeutic agent ([225Ac]-FPI-1434) is ongoing, which could prove to be promising for osteosarcoma treatment. Further studies should explore whether levels of IGF1R can be used as a biomarker to guide targeted therapy.

Utilizing mRNA expression data to predict outcomes independent of copy number results, our results indicate that FGFR2 and FIBIN can significantly predict overall survival in
both a discovery and validation set. FGFR2 mutations are associated with skeletal abnormalities [57]. Although a previous study implicated allelic loss in FGFR2 [58], allelic loss of this gene in our data was not predictive of either expression or survival (data not shown). FGFR2 expression was found to be reduced in osteosarcoma mouse models [59], but the mechanism by which FGFR2 is downregulated remains elusive. Reduced FGFR2 expression has been observed in multiple cancer types, including bladder [60], prostate [61], and liver [62] cancer, and deleterious mutations in FGFR2 have been implicated in melanoma [63]. In contrast, increased FGFR2 activity is found in several other cancers, including activating mutations in endometrial [64,65], lung [66], and gastric cancer [64], and amplifications and overexpression of FGFR2 in gastric and breast cancer [64]. FGFR2 is a tyrosine kinase receptor that is highly expressed in the cartilage of the growth plate, and plays a vital role in the differentiation of osteoblasts [67]. Furthermore, FGF signaling in the bone has been shown to induce apoptosis in differentiating osteoblasts [68]. Given that FGFR2 downregulation is significantly associated with both poor overall survival and event-free survival in our data, FGFR2 disruption may serve to inhibit differentiation in osteosarcoma. Further studies into how dysregulation of this gene’s expression affects osteosarcoma progression are warranted. FIBIN, a gene essential for pectoral fin bud growth in zebrafish [69], has a poorly understood function in humans, although expression is present in several tissues and may have functions in embryonic development [70]. Given that this gene was found to be differentially expressed in primary/metastatic osteosarcoma cell line pairs [71–73], and that it can be used for survival prediction in the present study, further examination of FIBIN in osteosarcoma may provide insights into its function.

The ability to clearly distinguish the large-scale genomic rearrangements and other sequence abnormalities that are characteristic of pediatric osteosarcoma in array-based studies is inferior to the resolution achieved with whole genome and exome sequencing. In addition, other mechanisms such as DNA methylation or microRNA may be used by tumor samples to alter gene expression. Therefore, the need for a comprehensive genomic and epigenomic characterization of osteosarcoma on large sample set is evident and necessary to identifying the underlying pathology and biology of the disease.

Using concurrent genomic platforms profiling on a substantial number of osteosarcoma samples, we were able to establish a correlation between IGF1R copy number and expression and an association with survival. In addition, we were able to identify and validate the prognostic significance of FGFR2 and FIBIN expression in predicting osteosarcoma outcome. Future studies may identify the exact mechanism behind the change in FGFR2 expression, as well as the role of the relatively uncharacterized gene FIBIN.

4. Materials and Methods

4.1. Patient Samples

Fresh frozen pre-treatment osteosarcoma samples were obtained from the Children’s Oncology Group (COG), the Children’s Cancer Group (CCG) and the Biopathology Center (BPC, Columbus, OH, USA). Before quality control, 226 unique patients were included in this study. Clinical survival data were available for 86% of the cases (n = 196) (Supplementary Table S3). Tissue was obtained from patients treated on several COG osteosarcoma protocols (P9851, P9754, INT0133, AOST0331, AOST0121) and one CCG protocol (CCG7943). Additional osteosarcoma samples not part of a protocol were obtained from the BPC. Samples eligible for protocols included a combination of initially non-metastatic and metastatic patients. All protocols were approved by the corresponding institutional review board at each participating institution. All patients/parental guardians provided consent to participate in the protocol. All patients involved in this study were under 32 years of age.

4.2. Single Nucleotide Polymorphism Array Profiling

DNA genotyping was performed using the Genome-Wide Human Single Nucleotide Polymorphism (SNP) 6.0 array (Affymetrix, Inc., Santa Clara, CA, USA). Arrays were profiled according to manufacturer’s recommendations. Quality control (QC) and geno-
typing of the SNP 6.0 array was performed in Affymetrix Power Tools (APT, v1.17.0). Affymetrix’s recommended contrast QC cutoff of <0.4 was used to filter out samples with poor quality. Three samples which did not pass this cutoff were excluded from further analysis. Genotyping using Birdseed v2 and allele-specific signal extraction was performed. PennCNV was used to generate log R ratio and b-allele frequencies for each sample, which were input to Allele-Specific Copy Number Analysis of Tumors, v2.1 (ASCAT) to calculate copy number [74,75]. ASCAT accounts for tumor ploidy and aberrant cell fraction in its copy number calculation and, more importantly to this study, can do so in the absence of matched germline DNA. In our study ASCAT successfully resolved 147 samples (Table 5, Supplementary Figure S6), resulting in 1 additional sample’s exclusion from the study, and subsequent segmentation was performed using ASPCF (allele-specific piecewise constant fitting). Recurrent copy number aberrations were detected using Genomic Identification of Significant Targets in Cancer (GISTIC, v2.0.22) using default settings [76]. Copy number of significant regions from GISTIC were classified into moderate and high levels of amplification and deletion. The distinction of high amplification or deletion was based on GISTIC’s algorithm while moderate amplification and deletion are called using the default input parameter of >0.1.

Table 5. Clinical study of summary set. Only samples used in analyses are displayed.

|                          | All Samples | HuEx Samples | U133 Samples | Copy Number Only Samples |
|--------------------------|-------------|--------------|--------------|--------------------------|
|                          | #           | %            | #            | %                        |
| Total                    | 214         | 100          | 103          | 100                      | 64          | 100          | 47          | 100          |
| Gender                   |             |              |              |                          |
| Male                     | 122         | 57           | 55           | 53                       | 36          | 56           | 31          | 66           |
| Female                   | 92          | 43           | 48           | 47                       | 28          | 44           | 16          | 34           |
| Age at Diagnosis         |             |              |              |                          |
| <12                      | 151         | 71           | 70           | 68                       | 46          | 72           | 35          | 74           |
| >12                      | 63          | 29           | 33           | 32                       | 18          | 28           | 12          | 26           |
| Location                 |             |              |              |                          |
| Leg/Foot                 | 183         | 86           | 90           | 87                       | 58          | 91           | 35          | 74           |
| Arm/Hand                 | 17          | 8            | 10           | 10                       | 2           | 3            | 5           | 11           |
| Other                    | 11          | 5            | 1            | 1                        | 4           | 6            | 6           | 13           |
| No Data                  | 3           | 1            | 2            | 2                        | 0           | 0            | 1           | 2            |
| SNP Data                 |             |              |              |                          |
| Yes                      | 147         | 69           | 93           | 90                       | 7           | 11           | 47          | 100          |
| No                       | 67          | 31           | 10           | 10                       | 57          | 89           | 0           | 0            |
| Event                    |             |              |              |                          |
| Occurred                 | 87          | 41           | 38           | 37                       | 31          | 48           | 18          | 38           |
| Censored                 | 100         | 47           | 50           | 49                       | 29          | 45           | 21          | 45           |
| No Data                  | 27          | 13           | 15           | 15                       | 4           | 6            | 8           | 17           |
| Death                    |             |              |              |                          |
| Occurred                 | 68          | 32           | 27           | 26                       | 28          | 44           | 13          | 28           |
| Censored                 | 119         | 56           | 61           | 59                       | 32          | 50           | 26          | 55           |
| No Data                  | 27          | 13           | 15           | 15                       | 4           | 6            | 8           | 17           |
| Metastasis at Diagnosis  |             |              |              |                          |
| No                       | 170         | 79           | 81           | 79                       | 54          | 84           | 35          | 74           |
| Yes                      | 44          | 21           | 22           | 21                       | 10          | 16           | 12          | 26           |

|                          | Mean | SD  | Mean | SD  | Mean | SD  | Mean | SD  |
|--------------------------|------|-----|------|-----|------|-----|------|-----|
| Age at Diagnosis         | 13.89| 3.78| 13.36| 3.6 | 14.4 | 3.65| 14.37| 4.25|
| Follow-up of Survivors   | 6.47 | 2.77| 6.83 | 2.78| 6.26 | 2.9 | 5.87 | 2.53|

4.3. mRNA Expression Profiling

Affymetrix U133 Plus 2.0 and Human Exon 1.0 ST arrays were used to profile mRNA expression. To assess sample quality, median absolute deviation (MAD) was plotted out for each array and outliers were observed visually. Seven samples were removed from the U133 Plus 2.0 dataset and 1 sample was removed from the Human Exon 1.0 ST dataset (Supplementary Figure S6). After removal of poor-quality cases, APT was used to perform robust multi-array average (RMA) normalization and calculate gene-centric average expression using annotations provided in NetAffx (hg19) [77]. Only core probesets with annotated genes were used in downstream analysis. Samples profiled on the Human Exon 1.0 ST array (n = 103) were used for the discovery set while samples profiled on the
U133 Plus 2.0 array \((n = 64)\) were used for validation (Table 5). Patients with data on both arrays were excluded from discovery set. For the discovery sample set, only the top 2.5% most variant probesets by interquartile range (437 probesets, IQR ≥ 1.433) were included in the survival analysis.

4.4. mRNA Clustering

In total, 103 samples profiled on the HuEx array were assigned to expression groups by non-negative matrix factorization (NMF) \((\text{method} = \text{brunet}, \text{run} = 1000, \text{seed} = 123456, k = 2 \text{ to } 6)\) of the top 10% most variant \((1747 \text{ probesets, IQR} ≥ 1.026)\) gene-specific probesets using the NMF package [78].

4.5. Differential Expression and Pathway Analysis

Differential expression of mRNAs was determined by extracting the features which contributed to NMF clustering. Genes mapping to differentially expressed probes were utilized for pathway enrichment analysis using MetaCore Process Networks enrichment (GeneGo Inc., St. Joseph, MI, USA), with the gene list for all probesets used as background.

4.6. Statistical Analysis

Cox proportional hazard regression models [79] adjusted for initial metastasis were used to calculate hazard ratios (HR) for event-free (EFS) and overall survival (OS). Wald test \(p\)-values were used to determine significance. Survival curves were generated using the Kaplan–Meier estimator [80].

Correction for multiple testing was performed using the Benjamini–Hochberg false discovery rate correction method [81]. Pearson correlation was used to compare copy number and expression platforms. All statistical analysis was performing in R using the stats and survival [82] packages.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms23148036/s1.

Author Contributions: Conceptualization, T.J.T., T.-K.M. and C.C.L.; methodology, A.M.T., J.M.S., A.Y., H.V., T.-K.M. and C.C.L.; software, A.M.T., J.M.S., A.Y., H.V. and T.-K.M.; formal analysis, A.M.T., J.M.S., A.Y., H.V. and T.-K.M.; investigation, A.M.T., J.M.S., A.Y., H.V., J.S., D.A.B., T.J.T., J.M.G.-F., T.-K.M. and C.C.L.; resources, J.S., D.A.B., T.J.T., J.M.G.-F., T.-K.M. and C.C.L.; data curation, A.M.T., J.M.S., A.Y., H.V., J.S., D.A.B., T.J.T., J.M.G.-F., T.-K.M. and C.C.L.; writing—original draft preparation, A.M.T., J.M.S., A.Y., H.V., J.S., T.-K.M. and C.C.L.; writing—review and editing, A.M.T., J.M.S., A.Y., H.V., J.S., T.-K.M. and C.C.L.; visualization, A.M.T., J.M.S., A.Y. and H.V.; supervision, T.-K.M. and C.C.L.; project administration, T.J.T., T.-K.M. and C.C.L.; funding acquisition, T.J.T., T.-K.M. and C.C.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by NCI, grant number U01 CA114757-04.

Institutional Review Board Statement: Ethical review and approval were waived for this study, as the sample data were anonymized by the Children’s Oncology Group as the honest broker prior to analysis. Additionally, the proposed study was submitted to the Institutional Review Board of Baylor College of Medicine, who confirmed that the study did not require ethical review.

Informed Consent Statement: Not applicable, as sample data was anonymized prior to analysis.

Data Availability Statement: The data presented in this study are available upon request via the COG’s High Dimensional Data (HDD) platform (datarequest@childrensoncologygroup.org).

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
References

1. Ries, L.A.G.; Smith, M.A.; Gurney, J.; Linet, M.; Tamara, T.; Young, J.; Bunin, G. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995; National Cancer Institute: Bethesda, MD, USA, 1999.

2. Rainusso, N.; Wang, L.L.; Yustein, J.T. The adolescent and young adult with cancer: State of the art-bone tumors. Curr. Oncol. Rep. 2013, 15, 296–307. [CrossRef] [PubMed]

3. Martin, J.W.; Squire, J.A.; Zielenksa, M. The genetics of osteosarcoma. Sarcoma 2012, 2012, 627254. [CrossRef] [PubMed]

4. Brun, J.; Dieudonne, F.X.; Marty, C.; Muller, J.; Schule, R.; Patino-Garcia, A.; Lecanda, F.; Fromigue, O.; Marie, P.J. FHL2 silencing reduces Wnt signaling and osteosarcoma tumorigenesis in vitro and in vivo. PLoS ONE 2013, 8, e55034. [CrossRef] [PubMed]

5. Rubin, E.M.; Guo, Y.; Tu, K.; Xie, J.; Zi, X.; Hoang, B.H. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol. Cancer Ther. 2010, 9, 1535–7163. [CrossRef] [PubMed]

6. Engin, F.; Bertin, T.; Ma, O.; Jiang, M.M.; Wang, L.; Sutton, R.E.; Donehower, L.A.; Lee, B. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum. Mol. Genet. 2009, 18, 1464–1470. [CrossRef]

7. Sadikovic, B.; Yoshimoto, M.; Chilton-MacNeill, S.; Thorner, P.; Squire, J.A.; Zielenksa, M. Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum. Mol. Genet. 2009, 18, 1962–1975. [CrossRef]

8. Khanna, C.; Wan, X.; Bose, S.; Cassaday, R.; Olomu, O.; Mendoza, A.; Yeung, C.; Gorlick, R.; Hewitt, S.M.; Helman, L.J. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med. 2004, 10, 182. [CrossRef]

9. Sadikovic, B.; Yoshimoto, M.; Al-Romaih, K.; Maire, G.; Zielenksa, M.; Squire, J.A. In vitro analysis of integrated global high-resolution DNA methylation profiling with genomic imbalance and gene expression in osteosarcoma. PLoS ONE 2008, 3, e2834. [CrossRef]

10. Zhang, W.; Qian, J.X.; Yi, H.L.; Yang, Z.D.; Wang, C.F.; Chen, J.Y.; Wei, X.Z.; Fu, Q.; Ma, H. The microRNA-29 plays a central role in osteosarcoma pathogenesis and progression. Mol. Biol. 2012, 46, 622–627. [CrossRef]

11. Cai, H.; Lin, L.; Cai, H.; Tang, M.; Wang, Z. Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. Med. Oncol. 2013, 30, 499. [CrossRef]

12. Gougelet, A.; Pissaloux, D.; Besse, A.; Perez, J.; Duc, A.; Dutour, A.; Blay, J.Y.; Alberti, L. Micro RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int. J. Cancer 2011, 129, 680–690. [CrossRef]

13. Zhao, G.; Cai, C.; Yang, T.; Qiu, X.; Liao, B.; Li, W.; Ji, Z.; Zhao, J.; Zhao, H.; Guo, M. MicroRNA-221 induces cell survival and cspilatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS ONE 2013, 8, e5906. [CrossRef]

14. Gao, Y.; Feng, B.; Han, S.; Zhang, K.; Chen, J.; Li, C.; Wang, R.; Chen, L. The Roles of MicroRNA-141 in Human Cancers: From Diagnosis to Treatment. Cell Physiol. Biochem. 2016, 38, 427–448. [CrossRef]

15. Maire, G.; Martin, J.W.; Yoshimoto, M.; Chilton-MacNeill, S.; Zielenksa, M.; Squire, J.A. Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet. 2011, 204, 138–146. [CrossRef]

16. Won, K.Y.; Kim, Y.W.; Kim, H.-S.; Lee, S.K.; Jung, W.-W.; Park, Y.-K. MicroRNA-199b-5p is involved in the Notch signaling pathway in osteosarcoma. Hum. Pathol. 2013, 44, 1648–1655. [CrossRef]

17. Miao, J.; Wu, S.; Peng, Z.; Tania, M.; Zhang, C. MicroRNAs in osteosarcoma: Diagnostic and therapeutic aspects. Tumour Biol. 2013, 34, 2093–2098. [CrossRef]

18. Ottaviani, G.; Jaffe, N. The epidemiology of osteosarcoma. Cancer Treat. Res. 2009, 152, 159–167. [CrossRef]

19. Goorin, A.M.; Schwartzentruber, D.J.; Devidas, M.; Gebhardt, M.C.; Ayala, A.G.; Harris, M.B.; Helman, L.J.; Grier, H.E.; Link, M.P.; Pediatric Oncology Group. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J. Clin. Oncol. 2003, 21, 1574–1580. [CrossRef]

20. Bielack, S.S.; Kempf-Bielack, B.; Delling, G.n.; Exner, G.U.; Flege, S.; Helmke, K.; Kotz, R.; Salzer-Kuntschik, M.; Werner, M.; Winkelmann, W. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol. 2002, 20, 776–790. [CrossRef]

21. Marina, N.; Gebhardt, M.; Teot, L.; Gorlick, R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004, 9, 422–441. [CrossRef]

22. Gualberto, A.; Pollak, M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: Early clinical trial results and future directions. Oncogene 2009, 28, 3009. [CrossRef]

23. Pappo, A.S.; Vassal, G.; Crowley, J.J.; Bolejack, V.; Hogendoorn, P.C.; Chugh, R.; Ladanyi, M.; Grippo, J.F.; Dall, G.; Staddon, A.P. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. Cancer 2014, 120, 2448–2456.

24. Man, T.K.; Lu, X.-Y.; Jaeweon, K.; Perlay, L.; Harris, C.P.; Shah, S.; Ladanyi, M.; Gorlick, R.; Lau, C.C.; Rao, P.H. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 2004, 4, 45. [CrossRef]

25. Freeman, S.S.; Allen, S.W.; Ganti, R.; Wu, J.; Ma, J.; Su, X.; Neale, G.; Dome, J.S.; Daw, N.C.; Khourey, J.D. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer Interdiscip. Int. J. Am. Cancer Soc. 2008, 113, 1453–1461.
26. Kuijjer, M.L.; Rydbeck, H.; Kresse, S.H.; Buddingh, E.P.; Lid, A.B.; Roelofs, H.; Bürger, H.; Myklebost, O.; Hogendoorn, P.C.; Meza-Zepeda, L.A. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. *Genes Chromosomes Cancer* 2012, 51, 696–706. [CrossRef]

27. Lockwood, W.W.; Stack, D.; Morris, T.; Grehan, D.; O’Keane, C.; Stewart, G.L.; Cumiskey, J.; Lam, W.L.; Squire, J.A.; Thomas, D.M. Cyclin E1 is amplified and overexpressed in osteosarcoma. *J. Mol. Diagn.* 2011, 13, 289–296. [CrossRef]

28. Bridge, J.A.; Nelson, M.; McComb, E.; McGuire, M.H.; Rosenthal, H.; Vergara, G.; Maale, G.E.; Spanier, S.; Neff, J.R. Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. *Cancer Genet. Cytogenet.* 1997, 95, 74–87. [CrossRef]

29. Mertens, F.; Mandahl, N.; Örndal, C.; Baldetorp, B.; Bauer, H.; Rydholm, A.; Wiebe, T.; Willen, H.; Åkerman, M.; Heim, S. Cytogenetic findings in 33 osteosarcomas. *Int. J. Cancer* 1993, 55, 44–50. [CrossRef]

30. Visani, G.; Sapienza, M.R.; Isidori, A.; Tripodo, C.; Laginestra, M.A.; Righi, S.; Sacchetti, C.A.S.; Gazzola, A.; Mannu, C.; Rossi, M. SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis. *PLoS ONE* 2011, 6, e27560. [CrossRef]

31. Melchor, L.; Saucedo-Cuevas, L.P.; Muñoz-Repeto, I.; Rodríguez-Pinilla, S.M.; Honrado, E.; Campoverde, A.; Palacios, J.; Nathanson, K.L.; García, M.J.; Benítez, J. Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. *Breast Cancer Res.* 2009, 11, R86. [CrossRef]

32. Day, E.; Pouloaganissis, G.; McLaughlan, F.; Mulholland, S.; Arends, M.J.; Ibrahim, A.E.; Dear, P.H. IR32 is a candidate drive oncogene on 13q34 in colorectal cancer. *Int. J. Exp. Pathol.* 2013, 94, 203–211. [CrossRef] [PubMed]

33. Liu, T.-T.; You, H.-L.; Weng, S.-W.; Wei, Y.-C.; Eng, H.-L.; Huang, W.-T. Recurrent amplification at 13q34 targets at CUL4A, IRS2, and TFDP1 as an independent prognosticator in Intrahepatic Cholangiocarcinoma. *PLoS ONE* 2015, 10, e0145388. [CrossRef] [PubMed]

34. Ulaner, G.A.; Hoffman, A.R.; Otero, J.; Huang, H.Y.; Zhao, Z.; Mazumdar, M.; Gorlick, R.; Meyers, P.; Healey, J.H.; Ladanyi, M. Divergent patterns of telomere maintenance mechanisms among human sarcomas: Sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing’s sarcomas and osteosarcomas. *Genes Chromosomes Cancer 2004*, 41, 155–162. [CrossRef]

35. Wadayama, B.; Toguchida, J.; Shimizu, T.; Ishizaki, K.; Sasaki, M.S.; Kotoura, Y.; Yamamuro, T. Mutation spectrum of the retinoblastoma gene in osteosarcomas. *Cancer Res.* 1994, 54, 3042–3048. [PubMed]

36. Araki, N.; Uchida, A.; Kimura, T.; Yoshikawa, H.; Aoki, Y.; Ueda, T.; Takai, S.; Miki, T.; Ono, K. Involvement of the retinoblastoma gene in osteosarcomas. *Ann. Oncol.* 2008, 19, 1500–1508. [CrossRef] [PubMed]

37. Scionti, I.; Michelacci, F.; Pasello, M.; Hattinger, C.M.; Alberghini, M.; Manara, M.C.; Bacci, G.; Ferrari, S.; Scotlandi, K.; Picci, P.; et al. Identification of chromosomal aberrations associated with disease progression and a novel 3q13.31 deletion involving LSAMP gene in osteosarcoma. *Int. J. Oncol.* 2015, 47, 1511–1519. [CrossRef]

38. Ueda, T.; Healey, J.H.; Huvos, A.G.; Ladanyi, M. Amplification of the MYC Gene in Osteosarcoma Secondary to Paget’s Disease of Bone. *Sarcoma* 1997, 1, 131–134. [CrossRef]

39. Shimizu, T.; Ishikawa, H.; Sugihara, E.; Kuninaka, S.; Miyamoto, T.; Mabuchi, Y.; Matsuzaki, Y.; Tsunoda, T.; Miya, F.; Morioka, H.; et al. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of apigogenesis. *Oncogene* 2010, 29, 5687–5699. [CrossRef]

40. Righi, A.; Gambarotti, M.; Longo, S.; Benini, S.; Gamberi, G.; Cocchi, S.; Vanel, D.; Picci, P.; Bertoni, F.; Simon, A.; et al. Small cell osteosarcoma: Clinicopathologic, immunohistochemical, and molecular analysis of 36 cases. *Am. J. Surg. Pathol.* 2015, 39, 691–699. [CrossRef]

41. Chow, J.P.; Poon, R.Y. The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery. *Oncogene* 2013, 32, 4778–4788. [CrossRef]

42. Shih, A.; Benassi, M.; Mohammedi, H.; Stavropoulos, D.S.; Baskin, R.; Ray, P.; Novokmet, A.; Malkin, D. Recurrent Focal Copy-Number Changes and Loss of Heterozygosity Implicate Two Noncoding RNAs and One Tumor Suppressor Gene at Chromosome 13q13.31 in Osteosarcoma. *Cancer Res.* 2010, 70, 160–171. [CrossRef]

43. Chen, Y.C.; Chen, W.M.; Chen, T.H.; Liu, W.Y.; Chen, J.C.; Chou, H.J.; Hung, G.Y.; Wu, H.T.; He, C.J.; Shiau, C.Y.; et al. Identification of chromosomal aberrations associated with disease progression and a novel 3q13.31 deletion involving LSAMP gene in osteosarcoma. *Int. J. Int. Oncol.* 2009, 35, 775–788. [CrossRef]

44. Yen, C.C.; Chen, W.M.; Chen, Y.C.; Chen, P.C.; Chiou, H.J.; Hung, G.Y.; Wu, H.T.; He, C.J.; Shiau, C.Y.; et al. Alternative lengthening of telomeres mechanism in Ewing’s sarcomas and osteosarcomas. *Int. J. Mol. Sci.* 2022, 23, 8036. [CrossRef]
48. Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat. Rev. Cancer 2012, 12, 159–169. [CrossRef]
49. Humbel, R.E. Insulin-like growth factors I and II. Eur. J. Biochem. 1990, 190, 445–462. [CrossRef]
50. Schmid, C. Insulin-like growth factors. Cell Biol. Int. 1995, 19, 445–457. [CrossRef]
51. Denley, A.; Cosgrove, L.J.; Booker, G.W.; Wallace, J.C.; Forbes, B.E. Molecular interactions of the IGF system. Cytokine Growth Factor Rev. 2005, 16, 421–439. [CrossRef]
52. Yu, H.; Mistry, J.; Nicar, M.J.; Khosravi, M.J.; Diamondis, A.; van Doorn, J.; Juul, A. Insulin-like growth factors (IGF-I, free IGF-I, and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. J. Clin. Lab. Anal. 1999, 13, 166–172. [CrossRef]
53. Rikhof, B.; de Jong, S.; Suurmeijer, A.J.; Meijer, C.; van der Graaf, W.T. The insulin-like growth factor system and sarcomas. J. Pathol. 2009, 217, 469–482. [CrossRef]
54. Burrow, S.; Andrulis, I.L.; Pollak, M.; Bell, R.S. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J. Surg. Oncol. 1998, 69, 21–27. [CrossRef]
55. Cao, Y.; Roth, M.; Piperdi, S.; Montoya, K.; Sowers, R.; Rao, P.; Geller, D.; Houghton, P.; Kolb, E.A.; Gill, J.; et al. Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma. PLoS ONE 2014, 9, e106249. [CrossRef]
56. Wagner, L.M.; Fouladi, M.; Ahmed, A.; Krailo, M.D.; Weigel, B.; DuBois, S.G.; Doyle, L.A.; Chen, H.; Blaney, S.M. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: Results from the Children’s Oncology Group. Pediatr. Blood Cancer 2015, 62, 440–444. [CrossRef]
57. Willkie, A.O.M.; Patey, S.J.; Kan, S.-h.; van den Ouweland, A.M.W.; Hamel, B.C.J. FGFs, their receptors, and human limb malformations: Clinical and molecular correlations. Am. J. Med. Genet. 2002, 112, 266–278. [CrossRef]
58. Mendoza, S.; David, H.; Gaylord, G.M.; Miller, C.W. Allergic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes. Cancer Genet. Cytogenet. 2005, 158, 142–147. [CrossRef]
59. Walkley, C.R.; Qudsi, R.; Sankaran, V.G.; Perry, J.A.; Gostissa, M.; Roth, S.I.; Rodda, S.J.; Snay, E.; Dunning, P.; Fahey, F.H.; et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008, 22, 1662–1676. [CrossRef]
60. Diez de Medina, S.G.; Chopin, D.; El Marjou, A.; Delouvee, A.; LaRochelle, W.J.; Hoznek, A.; Abbou, C.; Aaronson, S.A.; Thiery, J.P.; Radvanyi, F. Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene 1997, 14, 323–330. [CrossRef]
61. Naimi, B.; Latil, A.; Fournier, G.; Mangin, P.; Cussenot, O.; Berthon, P. Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate 2002, 52, 245–252. [CrossRef]
62. Amann, T.; Bataille, F.; Spruss, T.; Dettmer, K.; Wild, P.; Liedtke, C.; Muhlbauer, M.; Kiefer, P.; Oefner, P.; Trautwein, C.; et al. Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth. Am. J. Pathol. 2010, 176, 1433–1442. [CrossRef] [PubMed]
63. Gartsides, M.G.; Chen, H.; Ibrahim, O.A.; Byron, S.A.; Curtis, A.V.; Wellsell, C.L.; Bengston, A.; Yudt, L.M.; Eliseenkova, A.V.; Ma, J.; et al. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol. Cancer Res. 2009, 7, 41–54. [CrossRef] [PubMed]
64. Babina, I.S.; Turner, N.C. Advances and challenges in targeting FGFR signalling in cancer. Nat. Rev. Cancer 2017, 17, 318–332. [CrossRef] [PubMed]
65. Dutt, A.; Salvesen, H.B.; Chen, T.H.; Ramos, A.H.; Onofrio, R.C.; Hatton, C.; Nicoletti, R.; Winckler, W.; Grewal, R.; Hanna, M.; et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl. Acad. Sci. USA 2008, 105, 8713–8717. [CrossRef] [PubMed]
66. Greenman, C.; Stephens, P.; Smith, R.; Dalglish, G.L.; Hunter, C.; Bignall, G.; Davies, H.; Teague, J.; Butler, A.; Stevens, C.; et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446, 153–158. [CrossRef]
67. Su, N.; Jin, M.; Chen, L. Role of FGF/FGFR signaling in skeletal development and homeostasis: Learning from mouse models. Bone Res. 2014, 2, 1403. [CrossRef]
68. Mansukhani, A.; Bellosta, P.; Sahni, M.; Basilico, C. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J. Cell Biol. 2000, 149, 1297–1308. [CrossRef]
69. Nakahara, T.; Kusui, N.; Yamauchi, H.; Kimura, I.; Konishi, M.; Miyake, A.; Itoh, N. Fibin, a novel secreted lateral plate mesoderm signal, is essential for pectoral fin bud initiation in zebrafish. Dev. Biol. 2007, 303, 527–535. [CrossRef]
70. Lakner, J.; Seyer, C.; Herrmsdorf, T.; Schoneberg, T. Characterization of the expression, promoter activity and molecular architecture of fibin. BMC Biochem. 2011, 12, 26. [CrossRef]
71. Rhim, J.S.; Putman, D.L.; Arnstein, P.; Huebner, R.J.; McCallister, R.M. Characterization of human cells transformed in vitro by N-methyl-N'-nitro-N-nitosoguanidine. Int. J. Cancer 1977, 19, 505–510. [CrossRef]
72. Flores, R.J.; Li, Y.; Yu, A.; Shen, J.; Rao, P.H.; Lau, S.S.; Vannucci, M.; Lau, C.C.; Man, T.K. A systems biology approach reveals common metastatic pathways in osteosarcoma. BMC Syst. Biol. 2012, 6, 50. [CrossRef]
73. Fogh, J.; Fogh, J.M.; Orfeo, T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 1977, 59, 221–226. [CrossRef]
74. Wang, K.; Li, M.; Hadley, D.; Liu, R.; Glessner, J.; Grant, S.F.; Hakonarson, H.; Bucan, M. PennCNV: An integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. *Genome Res.* **2007**, *17*, 1665–1674. [CrossRef]

75. Van Loo, P.; Nordgard, S.H.; Lingjærde, O.C.; Russnes, H.G.; Rye, I.H.; Sun, W.; Weigman, V.J.; Marynen, P.; Zetterberg, A.; Naume, B. Allele-specific copy number analysis of tumors. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 16910–16915. [CrossRef]

76. Mermel, C.H.; Schumacher, S.E.; Hill, B.; Meyerson, M.L.; Beroukhim, R.; Getz, G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome Biol.* **2011**, *12*, R41. [CrossRef]

77. Meyer, L.R.; Zweig, A.S.; Hinrichs, A.S.; Karolchik, D.; Kuhn, R.M.; Wong, M.; Sloan, C.A.; Rosenbloom, K.R.; Roe, G.; Rhead, B. The UCSC Genome Browser database: Extensions and updates 2013. *Nucleic Acids Res.* **2012**, *41*, D64–D69. [CrossRef]

78. Gaujoux, R.; Seoighe, C. A flexible R package for nonnegative matrix factorization. *BMC Bioinform.* **2010**, *11*, 367. [CrossRef]

79. Cox, D.R. Regression models and life-tables. *J. R. Stat. Soc. Ser. B* **1972**, *34*, 187–202. [CrossRef]

80. Kaplan, E.L.; Meier, P. Nonparametric estimation from incomplete observations. *J. Am. Stat. Assoc.* **1958**, *53*, 457–481. [CrossRef]

81. Benjamini, Y.; Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J. R. Stat. Society. Ser. B* **1995**, *57*, 289–300. [CrossRef]

82. R Core Team. *R: A Language and Environment for Statistical Computing*, Vienna, Austria. Available online: http://www.R-project.org (accessed on 19 May 2013).